BioCentury | Jan 18, 2019
Company News

Spectrum divesting marketed products to focus on late-stage programs

...FDA-approved assets included in the deal are T cell lymphoma drugs Folotyn pralatrexate and Beleodaq belinostat...
...NASDAQ:SPPI), Henderson, Nev. Aurobindo Pharma Ltd. (NSE:AUROPHARMA; BSE:524804), Hyderabad, India Business: Cancer Chris Lieu Beleodaq, belinostat (IV PXD101, PXD101) Evomela...
BioCentury | Jan 17, 2019
Company News

Spectrum divesting marketed products to focus on late-stage programs

...FDA-approved assets included in the deal are T cell lymphoma drugs Folotyn pralatrexate and Beleodaq belinostat...
...colony-stimulating factor; HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 Chris Lieu Beleodaq, belinostat (IV PXD101, PXD101) Evomela...
BioCentury | May 12, 2017
Company News

Clinigen launches European managed access program for Beleodaq from Onxeo

...Clinigen Group plc (LSE:CLIN) launched a managed access program in Europe for Beleodaq belinostat from Onxeo...
...S.A. (Euronext:ONXEO; CSE:ONXEO) to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). Under the program, Beleodaq...
...Clinigen Group plc (LSE:CLIN), Burton-on-Trent, U.K. Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO), Paris, France Business: Cancer Julian Zhu Beleodaq belinostat Clinigen...
BioCentury | Feb 29, 2016
Company News

Onxeo, University of Navarra deal

...The university will conduct preclinical trials evaluating Onxeo’s Beleodaq belinostat and Livatag doxorubicin in combination with...
...half. Livatag, a nanoparticle formulation of doxorubicin, is in Phase III testing to treat HCC. Beleodaq...
BioCentury | Feb 1, 2016
Company News

Spectrum Pharmaceuticals, Servier deal

...deal covers Zevalin ibritumomab for follicular B cell non-Hodgkin’s lymphoma (NHL); Fotolyn pralatrexate and Beleodaq belinostat...
BioCentury | Dec 14, 2015
Clinical News

Beleodaq belinostat: Phase I data

...dose-escalation, U.S. Phase I BelCHOP trial in 18 evaluable patients with PTCL showed that IV belinostat...
...a Phase III trial evaluating belinostat plus CHOP chemotherapy as first-line treatment of PTCL. Beleodaq belinostat...
...S.A. (Euronext:ONXEO; CSE:ONXEO), Paris, France Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), Henderson, Nev. Product: Beleodaq belinostat ( IV PXD101...
BioCentury | Jun 22, 2015
Clinical News

Belinostat: Additional Phase I/II data

...patients in the Phase II portion of the open-label Phase I/II PXD101-CLN-14 trial showed that belinostat...
...commercialize belinostat in North America and India. Last year, FDA granted accelerated approval to Beleodaq belinostat...
...CSE:ONXEO), Paris, France Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), Henderson, Nev. Product: Belinostat ( Beleodaq ) ( IV PXD101...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

...dilation) and reduce postoperative ocular pain U.S. Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO)/Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) Beleodaq belinostat...
BioCentury | Nov 19, 2014
Financial News

Onxeo proposes EUR 35.4M rights offering

...receptor alpha 2 (ADRA2) agonist. Onxeo also is planning a Phase I study of Beleodaq belinostat...
...of Beleodaq in July. Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) has North American and Indian rights to Beleodaq...
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Cancer

...Phase II testing to treat solid tumors. Onxeo S.A. and Spectrum Pharmaceuticals Inc. market Beleodaq belinostat...
Items per page:
1 - 10 of 204